Catalent stock trades near acquisition price as Novo Nordisk deal reshapes outlook

Catalent Inc. (ISIN US1488061029) has become a classic event-driven name after Novo Nordisk agreed to acquire the contract drug manufacturer for an enterprise value of about $16.5 billion, and Catalent stock now largely trades in the shadow of that deal valuation according to recent market data in July 2026.

Deal values equity at around $11.5 billion

According to a Reuters report dated 5 February 2024, Novo Nordisk agreed to buy Catalent for an enterprise value of about $16.5 billion, including debt.

The same report noted that the deal values Catalent's equity at roughly $11.5 billion based on the agreed cash consideration, implying a substantial premium to the companys pre-deal market value at the time.

For investors, the spread between the agreed consideration and the current market capitalization now defines much of the potential upside or downside in Catalent stock, alongside regulatory and execution risks around the transaction.

Revenue of $1.07 billion in Q3 2024

In its financial update for the quarter ended 31 March 2024, Catalent reported net revenue of about $1.07 billion, as outlined in a summary of the companys results that has been widely cited in financial media in mid 2024.

The same quarterly disclosure indicated that Catalent generated a net loss of roughly $204 million in that period, illustrating the profitability challenges that had weighed on sentiment even before the acquisition announcement.

Compared with the equivalent quarter a year earlier, revenue in this reporting period was modestly lower, while the net loss widened, underscoring why a strategic buyer like Novo Nordisk was prepared to step in with a long term industrial rationale rather than a near term earnings story for Catalent stock.

Biologics and gene therapy services

Catalent generates a significant portion of its revenue from biologics manufacturing and related services, including fill-and-finish operations for injectable drugs such as GLP-1 therapies.

Public company materials for recent fiscal years highlight that biologics and softgel segments together account for well over half of the companys annual revenue, reflecting the strategic importance of complex modalities in its portfolio.

Catalent stock and market positioning

Recent quote data from major financial portals indicate that Catalent stock trades in a range that implies a market capitalization in the low double digit billions of dollars, broadly aligned with the equity value embedded in the Novo Nordisk offer and leaving a relatively narrow merger arbitrage spread.

For investors, that pricing suggests the market currently assigns a high probability to deal completion, with residual risk tied mainly to regulatory clearances and integration outcomes rather than standalone earnings momentum.